Qi Liu
Guiyang Medical University(CN)Institute of Physiology and Basic Medicine(RU)Affiliated Hospital of Guizhou Medical University(CN)The First People's Hospital of Guiyang(CN)Center for Clinical Research (United States)(US)China State Shipbuilding (China)(CN)University of South China(CN)Nanjing University of Aeronautics and Astronautics(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Statistical Methods in Clinical Trials, Health Systems, Economic Evaluations, Quality of Life
Most-Cited Works
- → FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy(2015)515 cited
- → Clinical targeting of HIV capsid protein with a long-acting small molecule(2020)403 cited
- → FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer(2015)366 cited
- → Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice(2019)340 cited
- → FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer(2014)339 cited
- → Model‐Informed Drug Development: Current US Regulatory Practice and Future Considerations(2019)